Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Journal of Clinical Oncology · 01.03.2026 · 44 (7) · 586-597
DOI: 10.1200/jco-25-02382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2026. Verfasst von Andrea Necchi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant cisplatin-based chemotherapy (NAC). However, many patients are ineligible for or refuse cisplatin. SunRISe-4 (ClinicalTrials.gov identifier: NCT04919512 ) is an open-label, multicenter, parallel-cohort phase II study assessing neoadjuvant gemcitabine intravesical system (TAR-200/gem-iDRS) plus cetrelimab or cetrelimab monotherapy in patients with MIBC. METHODS Adults with Eastern Cooperative Oncology Group performance status 0-1, cT2-T4a N0M0, ineligible/refusing NAC, and planned for RC were randomly assigned 5:3, stratified by transurethral resection of bladder tumor completeness (residual tumor ≤3 cm permitted) and T stage, to receive TAR-200 plus cetrelimab (cohort 1) or cetrelimab monotherapy (cohort 2). The primary end point was pathologic complete response (pCR) at RC. Secondary end points included recurrence-free survival (RFS) and safety. Exploratory end points included pathologic overall response (pOR; ≤ypT1N0) and circulating tumor (ct) and urinary tumor (ut) DNA molecular residual disease (MRD). Side-by-side descriptive efficacy summary was planned. RESULTS At the May 9, 2025, data cutoff, 159 patients were treated; 88 in cohort 1 and 46 in cohort 2 underwent RC. pCR, pOR, and 1-year RFS rates were 38%, 53%, and 77% in cohort 1 and 28%, 44%, and 64% in cohort 2, respectively. pCR rates were consistent across subgroups. No new safety signals were observed. Across cohorts, utDNA– status before RC (week 12) and utDNA clearance correlated with pCR ( P < 10 –5 and < 10 –3 , respectively). ctDNA– status at baseline and week 12 was associated with longer RFS compared with ctDNA+ status at the same time point ( P = .04 and 0.01, respectively). CONCLUSION TAR-200 plus cetrelimab provided higher pCR, pOR, and 1-year RFS rates compared with cetrelimab monotherapy, supporting further investigation of the neoadjuvant combination in MIBC. utDNA and ctDNA MRD results support further investigation as biomarkers for residual local and nonlocal disease, respectively.
Autor:innen und Institutionen
- Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Urology, University of Florida, Gainesville, FL.
- Urology Department, Hospital Universitario Virgen de la Victoria, IBIMA-Plataforma BIONAND, Málaga, Spain.
- Miami Cancer Institute, Miami, FL.
ORCID-Profile: Andrea Necchi, Félix Guerrero-Ramos, Rohan Garje, Bernadett Szabados, Charles C Peyton, Benjamin Pradere, Neal Shore, Martin Bögemann, Mark A Preston, Cinty Gong, Hussein Sweiti, Sarah P Psutka
Zitieren
APA
Necchi, A., Guerrero-Ramos, F., Crispen, P. L., Herrera-Imbroda, B., Garje, R., Szabados, B., Peyton, C. C., Pradere, B., Ku, J. H., Shore, N., Bögemann, M., Preston, M. A., Xylinas, E., Sanchez de Llano, C., Gong, C., Hasan, M., Urtishak, K., Battaglia, S., Stitou, H., …, & Psutka, S. P. (2026). Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. Journal of Clinical Oncology, 44(7), 586-597. https://doi.org/10.1200/jco-25-02382
Vancouver
Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, et al. Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. Journal of Clinical Oncology. 2026;44(7):586-597. doi:10.1200/jco-25-02382
BibTeX
@article{Necchi2026,
author = {Necchi, Andrea and Guerrero-Ramos, Félix and Crispen, Paul L and Herrera-Imbroda, Bernardo and Garje, Rohan and Szabados, Bernadett and Peyton, Charles C and Pradere, Benjamin and Ku, Ja Hyeon and Shore, Neal and Bögemann, Martin and Preston, Mark A and Xylinas, Evanguelos and Sanchez de Llano, Cristina and Gong, Cinty and Hasan, Mohamad and Urtishak, Karen and Battaglia, Sebastiano and Stitou, Hind and Bhanvadia, Sumeet and Sweiti, Hussein and Psutka, Sarah P},
title = {Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {7},
pages = {586--597},
doi = {10.1200/jco-25-02382}
}
EUVIMED